How Incepta Is Shaping Bangladesh's Vaccines Future

Bangladesh's Incepta group has launched its vaccine bulk manufacturing facility – a move that could have a significant impact on cost dynamics in a country that imports over 90 million doses of vaccines each year under its infant immunization plan. Incepta's chair Abdul Muktadir tells Scrip why this facility can make a difference and also outlines plans on the firm's tetravalent HPV vaccine.